云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01952 云顶新耀

已收盘 11-04 16:08:10

26.460

+1.220

+4.83%

最高26.800	最低25.180	成交量441.16万
今开25.560	昨收25.240	日振幅6.42%
总市值93.67亿	流通市值93.67亿	总股本3.54亿
成交额1.14亿	换手率1.25%	流通股本3.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"云顶新耀","latestPrice":26.46,"timestamp":1793779690004,"preClose":25.24,"halted":0,"volume":4411562,"delay":0,"changeRate":0.048335974643423235,"floatShares":354000000,"shares":354000000,"eps":-0.89,"marketStatus":"已收盘","change":1.22,"latestTime":"11-04 16:08:10","open":25.56,"high":26.8,"low":25.18,"amount":114268355,"amplitude":0.064184,"askPrice":26.48,"askSize":2500,"bidPrice":26.46,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":-0.175,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793842200000},"marketStatusCode":5,"adr":0,"listingDate":1602172800000,"exchange":"SEHK","adjPreClose":25.24,"openAndCloseTimeList":[[1793755800000,1793764800000],[1793768400000,1793779200000]],"volumeRatio":0.778305,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952","defaultTab":"news","newsList":[{"id":"1108759043","title":"云顶新耀发布10月股份变动月报表，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1108759043","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108759043?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:37","pubTimestamp":1793785040,"startTime":"0","endTime":"0","summary":"云顶新耀有限公司于2026年11月4日披露截至2026年10月31日止月份的股份变动月报表。公司本月新增发行172,150股普通股，主要来自首次公开发售后购股权计划的期权行使。根据披露，首发前员工购股权计划本月无新发行，首发后购股权计划有172,150份期权行使，另有8,427份期权失效。公告同时显示，截至10月31日，首发前员工购股权计划、首发后股份奖励计划及2026年股份计划下的部分未归属股份激励未来仍将有发行可能。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108184337","title":"异动解读｜云顶新耀盘中上涨5.39%，再办mRNA研发日提振市场关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1108184337","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108184337?lang=zh_cn&edition=full","pubTime":"2026-11-04 14:23","pubTimestamp":1793773417,"startTime":"0","endTime":"0","summary":"11月4日，云顶新耀盘中上涨5.39%，报26.6港元，成交额9190.22万港元。消息面上，公司近日举办mRNA技术平台研发日，披露自研AI新抗原序列预测算法与mRNA/LNP技术协同推进，平台已覆盖个性化新抗原疫苗、通用型肿瘤疫苗、免疫调节疫苗及in vivo CAR-T等前沿管线，带动市场对其自研平台临床验证进展的关注。进一步看，公司此前已披露EVM16首批人体数据，并推进EVM14临床，同时引入两名前莫德纳核心科学家以加速美国临床开发，显示mRNA平台正由技术布局走向临床验证阶段。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"云顶新耀上涨，mRNA研发日引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680532088","title":"云顶新耀（01952）再办mRNA研发日 自研平台步入临床验证关口","url":"https://stock-news.laohu8.com/highlight/detail?id=2680532088","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680532088?lang=zh_cn&edition=full","pubTime":"2026-11-04 10:59","pubTimestamp":1793761144,"startTime":"0","endTime":"0","summary":"从平台布局看，云顶新耀正在推进自研AI新抗原序列预测算法与mRNA/LNP技术的协同研发，已搭建起覆盖个性化新抗原疫苗、通用型肿瘤疫苗、免疫调节疫苗及in vivo CAR-T的前沿管线。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20261104/20261104105916_78681.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20261104/20261104105916_78681.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","01952","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136539542","title":"异动解读｜云顶新耀盘中下跌5.05%，机构评级转弱压制短线情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1136539542","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136539542?lang=zh_cn&edition=full","pubTime":"2026-11-03 13:05","pubTimestamp":1793682329,"startTime":"0","endTime":"0","summary":"11月3日，云顶新耀盘中下跌5.05%，报25.58港元，成交额6510.72万港元。消息面上，市场仍在消化此前机构观点转弱影响，短线风险偏好承压。较新的公开信息显示，瑞银已将公司评级下调至中性，并给出27元人民币目标价。此前公司曾因耐赋康销售强劲、上半年收入11.48亿元、归母净亏损收窄至594.4万元而获关注，但最新评级变化对估值修复节奏形成压制。公司为一家从事创新药及疫苗研发、临床开发、制造及商业化的生物制药企业，已布局肾病、抗感染及自身免疫性疾病产品管线。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"云顶新耀盘中下跌，机构评级转弱施压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680717785","title":"【券商聚焦】中信证券：国内医药板块业绩持续修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2680717785","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680717785?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:40","pubTimestamp":1793580014,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券发布2027年医疗健康行业投资策略，“十五五”开局之年，医药行业首次列为国家新兴支柱产业，紧随其后的价格机制优化改革 、支持创新药械高定价、以及推动商业医疗保险发展等行业增量改革政策趋势，叠加国内医药行业在创新领域集中兑现等产业内外催化因素驱动下，该机构看到2026H1国内医药板块业绩持续修复，尤其是创新药、创新器械等新兴产业板块。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994936","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","LU0588546209.SGD","02268","01530","02269","06990","06996","06160","LU0455707207.USD","01177","LU1794554557.SGD","HK0000320264.USD","09966","01951","IE00B031HY20.USD","LU1064131003.USD","02596","LU1226287529.USD","06078","02273","LU0348766576.USD","02162","159938","KCE","03759","LU2488822045.USD","01548","LU0823426480.USD","09939","LU0828237510.HKD","600030","00013","01276","02096","06821","BK0028","LU0348825331.USD","09996","KURE","01952","LU0607220059.USD","LU0708995153.HKD","LU0708995583.HKD","LU1969619763.USD","01801","01093","09926","LU0039217434.USD","LU0979878070.USD","06030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195887087","title":"云顶新耀（01952）将于11月16日线上召开发特别股东大会 审议与海森生物战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1195887087","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195887087?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:16","pubTimestamp":1793351812,"startTime":"0","endTime":"0","summary":"\\n\\n 其他安排：\\n 股权登记日为2026年11月10日16:30，11月11日至11月16日期间暂停股份过户登记。\\n 所有决议将以投票表决方式进行，结果将按港交所规定在交易所及公司网站公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198095899","title":"异动解读｜云顶新耀盘中下跌5.04%，机构下调评级后短线承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1198095899","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198095899?lang=zh_cn&edition=full","pubTime":"2026-10-30 10:03","pubTimestamp":1793325814,"startTime":"0","endTime":"0","summary":"10月30日，云顶新耀盘中下跌5.04%，报28.28港元，成交额5684.63万港元。消息面上，市场仍在消化此前机构观点转弱影响，短线风险偏好继续承压。较新的公开消息显示，瑞银已将公司评级下调至中性，并给出27元人民币目标价。此前公司曾因券商上调评级、耐赋康销售强劲及上半年收入11.48亿元、归母净亏损收窄至594.4万元而获资金回流，但近期股价表现反映市场更关注最新评级变化带来的压制。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"云顶新耀短线承压，机构下调评级引发抛售","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679644740","title":"港股异动 | 云顶新耀(01952.HK)早盘涨近5% 星必妥首次亮相全国心血管学术大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2679644740","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679644740?lang=zh_cn&edition=full","pubTime":"2026-10-29 11:14","pubTimestamp":1793243697,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01952","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118574885","title":"异动解读｜云顶新耀盘中上涨5.05%，机构上调评级后资金回流","url":"https://stock-news.laohu8.com/highlight/detail?id=1118574885","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118574885?lang=zh_cn&edition=full","pubTime":"2026-10-29 11:09","pubTimestamp":1793243377,"startTime":"0","endTime":"0","summary":"10月29日，云顶新耀盘中上涨5.05%，报29.92港元，成交额6325.88万港元。消息面上，市场继续交易此前机构观点转暖。月初有券商将公司评级上调至买入，主要基于耐赋康销售强劲、上半年收入达11.48亿元、归母净亏损收窄至594.4万元，non-IFRS经调整利润为9723.2万元，并预计后续多个产品推进有望贡献增量。公司为创新药生物科技企业，已布局肾病、抗感染及自身免疫性疾病管线，现阶段股价反弹亦与商业化进展预期改善有关。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"云顶新耀盘中上涨，机构上调评级资金回流","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150688542","title":"云顶新耀（01952）拟于2026年11月16日召开股东特别大会并暂停股份过户","url":"https://stock-news.laohu8.com/highlight/detail?id=1150688542","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150688542?lang=zh_cn&edition=full","pubTime":"2026-10-28 22:05","pubTimestamp":1793196328,"startTime":"0","endTime":"0","summary":"云顶新耀有限公司10月28日公告称，公司董事会已决定于2026年11月16日（星期一）召开股东特别大会。为厘定有权出席并在会上投票的股东资格，公司将自2026年11月11日（星期三）至2026年11月16日（星期一）暂停办理股份过户登记手续，期间公司将不受理任何股份过户申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184803634","title":"异动解读｜云顶新耀盘中下跌5.29%，瑞银下调评级至中性","url":"https://stock-news.laohu8.com/highlight/detail?id=1184803634","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184803634?lang=zh_cn&edition=full","pubTime":"2026-10-26 15:27","pubTimestamp":1792999651,"startTime":"0","endTime":"0","summary":"10月26日，云顶新耀盘中下跌5.29%，报29.02港元，成交额1.57亿港元。消息面上，市场仍在消化机构观点转弱影响，瑞银已将公司评级下调至中性，并给出27元人民币目标价，继续压制短线风险偏好。云顶新耀有限公司是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司。该公司已建立跨肾病、抗感染及自身免疫性疾病的产品管线。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"云顶新耀下跌，瑞银下调评级施压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112774455","title":"异动解读｜云顶新耀盘中下跌7.36%，瑞银下调评级至中性","url":"https://stock-news.laohu8.com/highlight/detail?id=1112774455","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112774455?lang=zh_cn&edition=full","pubTime":"2026-10-23 09:32","pubTimestamp":1792719159,"startTime":"0","endTime":"0","summary":"10月23日，云顶新耀盘中下跌7.36%，报31.24港元，成交额3673.89万港元。消息面上，市场继续消化机构观点转弱影响，瑞银已将公司评级下调至中性，并给出27元人民币目标价，直接压制短线风险偏好。此前公司股价曾因mRNA平台全球临床开发预期升温而连续走强，包括引入两名前莫德纳核心科学家、推进EVM16与EVM14临床等；在前期预期已明显抬升后，评级下调更容易触发获利盘回吐。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"云顶新耀盘中下跌，瑞银下调评级施压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187966219","title":"异动解读｜云顶新耀盘中下跌5.32%，瑞银下调评级至中性","url":"https://stock-news.laohu8.com/highlight/detail?id=1187966219","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187966219?lang=zh_cn&edition=full","pubTime":"2026-10-22 10:41","pubTimestamp":1792636897,"startTime":"0","endTime":"0","summary":"10月22日，云顶新耀盘中下跌5.32%，报34.14港元，成交额9755.72万港元。消息面上，市场最新交易的是机构观点转弱。瑞银已将公司评级下调至中性，并给出27元人民币目标价，对股价情绪形成直接压制。此前公司股价曾因mRNA平台全球临床开发预期升温而连续走强，包括引入两名前莫德纳核心科学家、推进EVM16与EVM14临床等；在前期预期抬升后，最新评级下调更易引发资金回吐。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"云顶新耀遭瑞银降级，股价承压走低","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677460856","title":"创新药股早盘延续涨势 再鼎医药及云顶新耀均涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677460856","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677460856?lang=zh_cn&edition=full","pubTime":"2026-10-21 10:52","pubTimestamp":1792551120,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端创新药股早盘延续涨势，截至发稿，再鼎医药（09688）上涨5.67%，报19.93港元；云顶新耀（01952）上涨5.21%，报35.56港元；映恩生物-B（09606）上涨2.61%，报173港元；康方生物（09926）上涨3.23%，报94.35港元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-21/doc-inivyaat6202848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK1574","BK4531","09688","ZLAB","BK1583","06978","BK4585","MEDX","IBBQ","BK1161","159992","BK4548","BK1588","LU2488822045.USD","BK4526","LNGR","BK4588","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677646635","title":"港股异动 | 创新药股延续涨势 多项重要数据将于ESMO公布 平台型BD接连落地传递信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2677646635","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677646635?lang=zh_cn&edition=full","pubTime":"2026-10-21 10:30","pubTimestamp":1792549810,"startTime":"0","endTime":"0","summary":"国金证券认为，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LNGR","IBBQ","09926","LU0417516738.SGD","LU2488822045.USD","IE00B5MMRT66.SGD","KCAI","BK1574","BK1588","LU0348735423.USD","BK4588","LU0634319403.HKD","HK0000252160.HKD","LU1961090484.USD","IE00B543WZ88.USD","BK1161","KURE","LU2476274308.USD","LU0348783233.USD","MEDX","LU1794554557.SGD","LU0561508036.HKD","LU0348825331.USD","LU2399975544.HKD","09688","LU0348784397.USD","VXUS","LU0348827113.USD","BK4585","LU0540923850.HKD","09606","LU2778985437.USD","HK0000252152.HKD","06978","159992","01952","LU0417516902.SGD","LU1720050803.USD","LU0348766576.USD","IE00BPRC5H50.USD","HK0000500386.USD","LU2476274720.SGD","BK1583","LU2543165471.USD","LU0348767384.USD","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149311793","title":"港股直击｜医药股及医药外包股续上扬，方达控股升 7%，歌礼制药、云顶新耀、金斯瑞生物升6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149311793","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149311793?lang=zh_cn&edition=full","pubTime":"2026-10-21 09:54","pubTimestamp":1792547682,"startTime":"0","endTime":"0","summary":"医药股及医药外包股续上扬，方达控股升 7%，歌礼制药、云顶新耀升、金斯瑞生物 6%，再鼎医药、心玮医疗、康希诺生物升 4%。","market":"hk","thumbnail":"https://static.tigerbbs.com/d17cb0ea313437e7afb8bad7f25dce9a","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/d17cb0ea313437e7afb8bad7f25dce9a"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","01672","01521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189391034","title":"异动解读｜云顶新耀盘中上涨5.03%，mRNA平台全球临床开发预期持续升温","url":"https://stock-news.laohu8.com/highlight/detail?id=1189391034","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189391034?lang=zh_cn&edition=full","pubTime":"2026-10-21 09:39","pubTimestamp":1792546742,"startTime":"0","endTime":"0","summary":"10月21日，云顶新耀盘中上涨5.03%，报35.5港元，成交额5321.4万港元。消息面上，市场继续交易公司自主mRNA平台全球临床开发提速预期。近期公司引入两名前莫德纳核心科学家，已披露其将重点推动mRNA技术平台在美国的临床开发，并与中国研发团队协作。与此同时，个性化肿瘤治疗性疫苗EVM16已交出首批人体数据，通用现货型肿瘤相关抗原疫苗EVM14正推进临床，强化平台进入临床验证阶段的信号。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"云顶新耀异动上涨，mRNA临床提速引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676665575","title":"创新药概念强势 翰森制药（03692）涨逾7% 前三季对外技术授权约1300亿美元接近25年全年","url":"https://stock-news.laohu8.com/highlight/detail?id=2676665575","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676665575?lang=zh_cn&edition=full","pubTime":"2026-10-20 11:23","pubTimestamp":1792466598,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念强势，截至发稿，乐普生物 涨8.81%，翰森制药涨7.06%，药明生物涨6.74%，晶泰控股涨4.56%，康诺亚-B涨4.70%，亚盛医药涨4.30%，恒瑞医药涨4.16%，药明合联涨3.96%，云顶新耀涨3.89%，和黄医药涨3.68%，中国生物制药涨3.24%，石药集团涨3.16%，科伦博泰生物涨3.14%，诺诚健华涨3.08%。消息面上，据人民财讯，10月20日，国家发展改革委召开10月份新闻发布会，会上提到，我国前三季度创新药对外技术授权约1300亿美元，接近去年全年。","market":"fut","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993987","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","BK1589","IE0008369823.USD","LU0072913022.USD","LU0417516902.SGD","02228","BK1576","LU1993786604.SGD","BK1610","LU1008478684.HKD","LU1794554557.SGD","KURE","LU0359201885.HKD","09969","03692","02268","IBBQ","LU0348827113.USD","LU1720050803.USD","LU2488822045.USD","MEDX","01093","BK1521","01952","LU1188198961.HKD","06978","01177","LU0196878994.USD","LU1152091754.HKD","LU0052750758.USD","BK1161","02162","LU2476274720.SGD","LU0043850808.USD","LU1226288170.HKD","LNGR","LU1242518931.SGD","LU0211977185.USD","LU1242518857.USD","LU2543165471.USD","00013","06855","02269","02157","LU0588546209.SGD","06990","LU0417516738.SGD","LU0979878070.USD","LU0128522744.USD","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166806173","title":"异动解读｜云顶新耀盘中上涨5.5%，mRNA平台全球临床开发预期持续升温","url":"https://stock-news.laohu8.com/highlight/detail?id=1166806173","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166806173?lang=zh_cn&edition=full","pubTime":"2026-10-20 11:22","pubTimestamp":1792466548,"startTime":"0","endTime":"0","summary":"10月20日，云顶新耀盘中上涨5.5%，报34.12港元，成交额1.39亿港元。消息面上，公司此前引入两名前莫德纳核心科学家，市场继续交易其自主mRNA平台全球临床开发提速预期。已披露信息显示，新任高管将重点推动公司mRNA技术平台在美国的临床开发，并与中国研发团队协作。公司个性化肿瘤治疗性疫苗EVM16已交出首批人体数据，通用现货型肿瘤相关抗原疫苗EVM14正推进临床，强化了平台进入临床验证阶段的信号。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"云顶新耀上涨，mRNA平台临床预期升温","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675685566","title":"港股异动 | 云顶新耀(01952.HK)涨超7% 引入两名前莫德纳核心科学家 自主mRNA平台全球临床开发有望提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2675685566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675685566?lang=zh_cn&edition=full","pubTime":"2026-10-16 14:21","pubTimestamp":1792131686,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01952","BK1583","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":-0.0966},{"period":"1month","weight":-0.1187},{"period":"3month","weight":-0.027},{"period":"6month","weight":-0.2528},{"period":"1year","weight":-0.4887},{"period":"ytd","weight":-0.3175}],"compareEarnings":[{"period":"1week","weight":0.021},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.0922},{"period":"6month","weight":-0.1164},{"period":"1year","weight":-0.1006},{"period":"ytd","weight":-0.0821}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"云顶新耀有限公司是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司。该公司已建立跨肾病、抗感染及自身免疫性疾病的产品管线。该公司的产品管线包括用于肾病治疗领域的耐赋康（TARPEYO）、用于治疗包括临床常见的革兰氏阴性菌、革兰氏阳性菌、厌氧菌等多重耐药菌的感染的依嘉（依拉环素）等产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.01035},{"month":2,"riseRate":0.333333,"avgChangeRate":0.039331},{"month":3,"riseRate":0.333333,"avgChangeRate":0.002002},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.092533},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.045773},{"month":6,"riseRate":0.666667,"avgChangeRate":0.224714},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.090363},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.046758},{"month":9,"riseRate":0.5,"avgChangeRate":0.026462},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.037283},{"month":11,"riseRate":0.428571,"avgChangeRate":0.064425},{"month":12,"riseRate":0.666667,"avgChangeRate":0.131823}],"exchange":"SEHK","name":"云顶新耀","nameEN":"EVEREST MED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云顶新耀,01952,云顶新耀股票,云顶新耀股票老虎,云顶新耀股票老虎国际,云顶新耀行情,云顶新耀股票行情,云顶新耀股价,云顶新耀股市,云顶新耀股票价格,云顶新耀股票交易,云顶新耀股票购买,云顶新耀股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}